Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531]
1 University of Siena, Siena, Italy; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy; NIBIT Foundation Onlus, Italy. Electronic address: annamaria.digiacomo@unisi.it.
2 Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
3 Unit of Melanoma, Medical Oncology, Department of Medical Oncology and Hematology, Istituto Nazionale dei Tumori, Milan, Italy.
4 Department of Oncology Gruppo Multimedica, Milan, Italy.
5 Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
6 Dermatology Clinic, Department of Medical Science, University of Turin, Italy.
10 Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
11 NIBIT Foundation Onlus, Italy.
12 University of Perugia, Santa Maria della Misericordia, University Hospital of Perugia, Italy.
13 Statistics, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
14 University of Siena, Siena, Italy; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy; NIBIT Foundation Onlus, Italy.